At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 77 enrolled
Drug / intervention
FluarixTM +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Immunogenicity and Safety Study of GSK Biologicals' Seasonal (2010-2011) Influenza Vaccine FluarixTM in Adolescents Previously Vaccinated With GSK Biologicals' H1N1 Vaccine PandemrixTM
In Brief
A Phase 4 clinical trial evaluating FluarixTM and HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old) for Influenza. Completed, enrolled 77 participants across 1 site.
Detailed Summary
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' FluarixTM vaccine in children who have previously been vaccinated with one dose of PandemrixTM at the age of 10-17 years.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesFinland
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2010
Enrollment StartOct 2010
Primary CompletionJul 2011
TodayJul 2026
First PostedAug 27, 2010
Enrollment StartOct 4, 2010
Primary CompletionJul 7, 2011
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.8 years ago
Interventions
FluarixTMbiological
One Intramuscular injection
HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)biological
Two Intramuscular injections